Drug selection and treatment monitoring via minimally invasive liquid biopsy using circulating tumor cells (CTCs) are expected to be realized in the near future. For clinical applications of CTCs, simple, high-throughput, single-step CTC isolation from whole blood without red blood cell (RBC) lysis and centrifugation remains a crucial challenge. In this study, we developed a novel cancer cell separation chip, “hybrid double-spiral chip”, that involves the serial combination of two different Dean flow fractionation (DFF) separation modes of half and full Dean cycles, which is the hybrid DFF separation mode for ultra-high-throughput blood processing at high precision and size-resolution separation. The chip allows fast processing of 5 mL whole blood within 30 min without RBC lysis and centrifugation. RBC and white blood cell (WBC) depletion rates of over 99.9% and 99%, respectively, were achieved. The average recovery rate of spiked A549 cancer cells was 87% with as low as 200 cells in 5 mL blood. The device can achieve serial reduction in the number of cells from approximately 1010 cells of whole blood to 108 cells, and subsequently to an order of 106 cells. The developed method can be combined with measurements of all recovered cells using imaging flow cytometry. As proof of concept, CTCs were successfully enriched and enumerated from the blood of metastatic breast cancer patients (N = 10, 1–69 CTCs per 5 mL) and metastatic prostate cancer patients (N = 10, 1–39 CTCs per 5 mL). We believe that the developed method will be beneficial for automated clinical analysis of rare CTCs from whole blood.
Background/Objectives: Liquid biopsy methods have gained prominence as minimally invasive tools to improve cancer treatment outcomes. Circulating tumor cells (CTCs) offer valuable insights into both primary and metastatic lesions. However, validating the CTC test results requires confirmation that the detected cells originate from cancer tissue. While studies have identified CTCs in colorectal cancer (CRC) patients using molecular markers, simultaneous validation of their cancer tissue origin remains unexplored. Methods: This study introduces a simple approach to detect adenomatous polyposis coli (APC) gene abnormalities alongside established CTC markers using a molecular imaging flow cytometer (MI-FCM). Given that APC gene abnormalities occur in 60–70% of CRC patients, their detection serves as strong evidence of cancer origin. Results: Our method achieved 92% concordance with DNA sequence analysis of tumor-derived cells. In a proof-of-concept study using 5 mL of whole blood from CRC patients, we observed a high frequency of cells exhibiting APC abnormalities, cytokeratin (CK), and vimentin (Vim) expression. Extending the study to 80 CRC patients across pathological stages I–IV confirmed CK and Vim as valid CTC markers. Three distinct cell populations were identified in blood: CK+/Vim−, CK+/Vim+, and CK−/Vim+. CTC number and frequency increased progressively with cancer stage. Conclusions: This is the first report demonstrating CK and Vim as effective markers for direct CTC detection in CRC patients. Our findings provide evidence-based validation of CTC markers, offering new insights and advancing approaches for patient care.
1 February 2026 in Review of Scientific Instruments
Most portable gas chromatographs (GCs) were designed exclusively for gas samples. If they can handle liquid samples too, the range of application is expected to expand substantially. However, in general, the injection volume of liquid samples in GCs is limited to about 1 μl or less to prevent the loss of analytical precision and instrument contamination. Therefore, it is difficult to achieve sufficient sensitivity with the limited resources of the portable GCs. In this study, we developed a large volume injection (LVI) technique applicable to portable GCs, fabricated a compact LVI–GC using a spherical surface acoustic wave (SAW) sensor (the ball SAW sensor) as the detector, and confirmed its basic operation. Using a sample mixture of linear alkanes with 7–13 carbons in a pentane solvent, we evaluated measurement conditions without the loss of analyte in a sample volume range of ∼5–50 μl and confirmed the linearity of the response with respect to the sample volume. In addition, 1,2-methylenedioxybenzene, a simulant of a hallucinogen, 3,4-methylenedioxymethamphetamine (MDMA), was analyzed for an application in drug analysis in urine, and a detection limit of ∼23 ng/ml, well below the cutoff value of ∼250 ng/ml for MDMA, was achieved. Furthermore, we found a correlation between the response of the ball SAW sensor and the retention index and investigated the possibility of quantitative analysis using retention indices.